Drugs / BACMUNE
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04452643 Comparator | Oct 2020 → Dec 2021 | COVID-19 | Inmunotek S.L. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BACMUNE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04452643 ↗ |
| Known as | MV130 | “BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)” NCT04452643 ↗ |
| Modality | Other / unclassified | “BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria” NCT04452643 ↗ |